215 related articles for article (PubMed ID: 32096040)
1. Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?
Fernandez-Gomez F; Tran H; Dhaenens CM; Caillet-Boudin ML; Schraen-Maschke S; Blum D; Sablonnière B; Buée-Scherrer V; Buee L; Sergeant N
Adv Exp Med Biol; 2019; 1184():207-216. PubMed ID: 32096040
[TBL] [Abstract][Full Text] [Related]
2. Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.
Caillet-Boudin ML; Fernandez-Gomez FJ; Tran H; Dhaenens CM; Buee L; Sergeant N
Front Mol Neurosci; 2014 Jan; 6():57. PubMed ID: 24409116
[TBL] [Abstract][Full Text] [Related]
3. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
Cho DH; Tapscott SJ
Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
[TBL] [Abstract][Full Text] [Related]
4. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2.
Timchenko L
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
Meola G
Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843
[TBL] [Abstract][Full Text] [Related]
6. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.
Bachinski LL; Baggerly KA; Neubauer VL; Nixon TJ; Raheem O; Sirito M; Unruh AK; Zhang J; Nagarajan L; Timchenko LT; Bassez G; Eymard B; Gamez J; Ashizawa T; Mendell JR; Udd B; Krahe R
Neuromuscul Disord; 2014 Mar; 24(3):227-40. PubMed ID: 24332166
[TBL] [Abstract][Full Text] [Related]
7. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
8. Neuropathology of classic myotonic dystrophy type 1 is characterized by both early initiation of primary age-related tauopathy of the hippocampus and unique 3-repeat tauopathy of the brainstem.
Hamasaki H; Maeda N; Sasagasako N; Honda H; Shijo M; Mori SI; Yagita K; Arahata H; Iwaki T
J Neuropathol Exp Neurol; 2022 Dec; 82(1):29-37. PubMed ID: 36331500
[TBL] [Abstract][Full Text] [Related]
9. Genetic and sporadic forms of tauopathies-TAU as a disease driver for the majority of patients but the minority of tauopathies.
Zempel H
Cytoskeleton (Hoboken); 2024 Jan; 81(1):66-70. PubMed ID: 37795931
[TBL] [Abstract][Full Text] [Related]
10. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2.
Vihola A; Bachinski LL; Sirito M; Olufemi SE; Hajibashi S; Baggerly KA; Raheem O; Haapasalo H; Suominen T; Holmlund-Hampf J; Paetau A; Cardani R; Meola G; Kalimo H; Edström L; Krahe R; Udd B
Acta Neuropathol; 2010 Apr; 119(4):465-79. PubMed ID: 20066428
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of muscle atrophy in myotonic dystrophies.
Timchenko L
Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888
[TBL] [Abstract][Full Text] [Related]
12. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24.
Le Ber I; Martinez M; Campion D; Laquerrière A; Bétard C; Bassez G; Girard C; Saugier-Veber P; Raux G; Sergeant N; Magnier P; Maisonobe T; Eymard B; Duyckaerts C; Delacourte A; Frebourg T; Hannequin D
Brain; 2004 Sep; 127(Pt 9):1979-92. PubMed ID: 15215218
[TBL] [Abstract][Full Text] [Related]
13. RNA pathogenesis of the myotonic dystrophies.
Day JW; Ranum LP
Neuromuscul Disord; 2005 Jan; 15(1):5-16. PubMed ID: 15639115
[TBL] [Abstract][Full Text] [Related]
14. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2).
Botta A; Caldarola S; Vallo L; Bonifazi E; Fruci D; Gullotta F; Massa R; Novelli G; Loreni F
Biochim Biophys Acta; 2006 Mar; 1762(3):329-34. PubMed ID: 16376058
[TBL] [Abstract][Full Text] [Related]
15. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
[TBL] [Abstract][Full Text] [Related]
16. Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing.
Dhaenens CM; Tran H; Frandemiche ML; Carpentier C; Schraen-Maschke S; Sistiaga A; Goicoechea M; Eddarkaoui S; Van Brussels E; Obriot H; Labudeck A; Gevaert MH; Fernandez-Gomez F; Charlet-Berguerand N; Deramecourt V; Maurage CA; Buée L; Lopez de Munain A; Sablonnière B; Caillet-Boudin ML; Sergeant N
Biochim Biophys Acta; 2011 Jul; 1812(7):732-42. PubMed ID: 21439371
[TBL] [Abstract][Full Text] [Related]
17. Myotonic Dystrophies: A Genetic Overview.
Soltanzadeh P
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205411
[TBL] [Abstract][Full Text] [Related]
18. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
Meola G; Cardani R
Neurol Sci; 2017 Apr; 38(4):535-546. PubMed ID: 28078562
[TBL] [Abstract][Full Text] [Related]
19. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease.
Maurage CA; Udd B; Ruchoux MM; Vermersch P; Kalimo H; Krahe R; Delacourte A; Sergeant N
Neurology; 2005 Nov; 65(10):1636-8. PubMed ID: 16301494
[TBL] [Abstract][Full Text] [Related]
20.
Bosè F; Renna LV; Fossati B; Arpa G; Labate V; Milani V; Botta A; Micaglio E; Meola G; Cardani R
Front Neurol; 2019; 10():992. PubMed ID: 31611837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
